PBAC's latest decision on Fluticasone furoate / vilanterol trifenatate: Recommended with restriction (2014). Considered for Regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination product (long-acting beta-2 agonist and inhaled corticosteroid) is appropriate.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2014
Submissions
1
2014 → 2014
Eligible population
Adults and adolescents aged 12 years and older with asthma who are symptomatic on inhaled corticosteroids with 'as needed' short-acting beta-2 agonist, or already on both an inhaled corticosteroid and a long-acting beta-2 agonist.